tiprankstipranks

FCGSX Mutual Fund Forecast & Price Targets

See the Price Targets and Ratings of:

FCGSX Analyst Rating

Moderate Buy
357ConsensusRatings
297 Buy
56 Hold
4 Sell
Based on the consensus analyst ratings on 357 stocks held in FCGSX.
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

FCGSX Analyst Price Target

Average Price Target

$25.95
Based on 357 Wall Street analysts offering 12 month price targets to Fidelity Series Growth Company Fund holdings in the last 3 months. The average price target is $25.95 with a high forecast of $31.62 and a low forecast of $19.74. The average price target represents a 17.52% change from the last price of $22.08.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","23":"$23","32":"$32","18.5":"$18.5","27.5":"$27.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":31.616,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$31.62</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.949,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$25.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.741,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$19.74</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,18.5,23,27.5,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2023","6":"Oct<br/>2023","9":"Jan<br/>2024","12":"Apr<br/>2024","25":"Apr<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n              \n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.53,23.228923076923078,23.927846153846154,24.62676923076923,25.325692307692307,26.024615384615384,26.72353846153846,27.42246153846154,28.121384615384613,28.820307692307694,29.519230769230766,30.218153846153847,30.917076923076923,{"y":31.616,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.53,22.793000000000003,23.056,23.319000000000003,23.582,23.845000000000002,24.108,24.371000000000002,24.634,24.897000000000002,25.16,25.423000000000002,25.686,{"y":25.949,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.53,22.31546153846154,22.100923076923078,21.886384615384618,21.671846153846154,21.457307692307694,21.24276923076923,21.02823076923077,20.813692307692307,20.599153846153847,20.384615384615383,20.170076923076923,19.95553846153846,{"y":19.741,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.89,"date":1680480000000,"info":"<div>Price: <b>$16<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.08,"date":1682899200000,"info":"<div>Price: <b>$16<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.42,"date":1685577600000,"info":"<div>Price: <b>$17<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":18.28,"date":1688342400000,"info":"<div>Price: <b>$18<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":18.94,"date":1690848000000,"info":"<div>Price: <b>$19<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":18.84,"date":1693526400000,"info":"<div>Price: <b>$19<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.67,"date":1696204800000,"info":"<div>Price: <b>$18<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.34,"date":1698796800000,"info":"<div>Price: <b>$17<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":19.12,"date":1701388800000,"info":"<div>Price: <b>$19<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":19.16,"date":1704153600000,"info":"<div>Price: <b>$19<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.4,"date":1706745600000,"info":"<div>Price: <b>$20<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.28,"date":1709251200000,"info":"<div>Price: <b>$22<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.53,"date":1711929600000,"info":"<div>Price: <b>$23<b/></div>","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$31.62Average Price Target$25.95Lowest Price Target$19.74
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

FCGSX Stocks With Highest Upside Potential

Name
Price & Change
Analyst Consensus
Analyst Price Target
xxxxxxxxxxxxxxxxxxxxxxxxxxx
aTyr Pharma Inc.
4 Buy
0 Hold
0 Sell
Strong Buy
xxxxxxxxxxxxxxxxxxxxxxxxxxx
Vor Biopharma, Inc.
8 Buy
0 Hold
0 Sell
Strong Buy
xxxxxxxxxxxxxxxxxxxxxxxxxxx
Sagimet Biosciences, Inc. Class A
3 Buy
0 Hold
0 Sell
Strong Buy
xxxxxxxxxxxxxxxxxxxxxxxxxxx
Seres Therapeutics Inc.
3 Buy
0 Hold
1 Sell
Moderate Buy
xxxxxxxxxxxxxxxxxxxxxxxxxxx
Poseida Therapeutics, Inc.
4 Buy
0 Hold
0 Sell
Strong Buy

FCGSX Stocks With Highest Downside Potential

Name
Price & Change
Analyst Consensus
Analyst Price Target
xxxxxxxxxxxxxxxxxxxxxxxxxxx
Synlogic Inc
0 Buy
3 Hold
0 Sell
Hold
xxxxxxxxxxxxxxxxxxxxxxxxxxx
IDIA
Idorsia Ltd
0 Buy
1 Hold
2 Sell
Moderate Sell
xxxxxxxxxxxxxxxxxxxxxxxxxxx
WK Kellogg Co
0 Buy
4 Hold
2 Sell
Moderate Sell
xxxxxxxxxxxxxxxxxxxxxxxxxxx
ARM Holdings PLC ADR
11 Buy
6 Hold
1 Sell
Moderate Buy
xxxxxxxxxxxxxxxxxxxxxxxxxxx
SharkNinja, Inc.
5 Buy
2 Hold
0 Sell
Moderate Buy

FCGSX Mutual Fund FAQ

What is FCGSX’s average 12-month price target, according to analysts?
Based on analyst ratings, Fidelity Series Growth Company Fund’s 12-month average price target is $25.95.
    What is FCGSX’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for FCGSX, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is FCGSX a Buy, Sell or Hold?
        Fidelity Series Growth Company Fund has a conensus rating of Moderate Buy which is based on 297 buy ratings, 56 hold ratings and 4 sell ratings.
          What is Fidelity Series Growth Company Fund’s price target?
          The average price target for Fidelity Series Growth Company Fund is $25.95. This is based on 357 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $31.62 ,the lowest forecast is $19.74. The average price target represents N/A Increase from the current price of N/A.
            What do analysts say about Fidelity Series Growth Company Fund?
            Fidelity Series Growth Company Fund’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 357 Wall Streets Analysts.
              How can I buy shares of FCGSX?
              Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis